Is Wall Street Bullish or Bearish on Bio-Techne Stock?
Analysts covering Bio-Techne (TECH) have a consensus 'Hold' rating, with one 'Strong Buy' and one 'Strong Sell' among 15. This is less bullish than a month ago. Wells Fargo downgraded TECH to 'Equal Weight' with a $73 price target, above the mean target of $70.46. TECH trades above this average.
How this was made
The 30-second read
Why it matters
The downgrade could trigger short-term price weakness and affect related biotech stocks.
Market read
Analyst rating change provides fresh guidance for traders.
What to watch
Recent product pipeline updates not reflected in the downgrade.
Background
Analyst consensus shifted from more bullish to a Hold stance after a downgrade.
Ticker impact
Wells Fargo downgraded TECH to Equal Weight with a $73 price target, shifting consensus to Hold.
Potential short-term downside of 2-4%
Downgrade and lower target suggest reduced upside, likely prompting sell pressure.
Market effects
May weigh on biotech sector sentiment as a major broker reduces rating.
Limited to US markets where TECH trades.
Minimal global impact.
Counterpoint
Some investors may view the downgrade as an overreaction and see buying opportunity.
Key entities
- AnalystWells Fargo & Company
Downgraded TECH to Equal Weight.
- CompanyBio-Techne
Subject of the analyst downgrade.
